Document is current

Documents that mention this clinical trial

<i>In situ</i> immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
https://doi.org/10.1136/jitc-2020-000940

Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
https://doi.org/10.1136/jitc-2021-002484

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma
https://doi.org/10.1136/jitc-2022-004643

Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.950

Documents that mention this clinical trial

<i>In situ</i> immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
https://doi.org/10.1136/jitc-2020-000940

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results
https://doi.org/10.1136/jitc-2022-sitc2022.0605

303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
https://doi.org/10.1136/jitc-2020-sitc2020.0303

B cells imprint adoptively transferred CD8 ⁺ T cells with enhanced tumor immunity
https://doi.org/10.1136/jitc-2021-003078

Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695

1072 Noninvasive detection of immunotherapy-related cardiac effects using [ ¹ ⁸ F]F-AraG PET
https://doi.org/10.1136/jitc-2025-sitc2025.1072